Anasayfa » News » Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPC

Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPC

Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPC
You May Be Interested In:Preteen Lipid Testing: Finger Pricks and Fast Results



(MedPage Today) — SAN FRANCISCO — The addition of radionuclide therapy with 177Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (CRPC), according…

share Paylaş facebook pinterest whatsapp x print

Similar Content

A photo of longshoremen on strike outside of Red Hook Terminal in Brooklyn, New York.
Opinion | How Physicians Can Unionize and Strike With Compassion November 2, 2024
Steffi Cao
This Viral, Fruit-Headed Doll And Its Tiny Penis Is Everyone’s Emotional Support Crutch April 6, 2023
Endo Break over a computer rendering of a man with illustrated body organs.
Imcivree Label Expanded; Weight Loss With Weekly Injection; Kidney Donation Chain December 24, 2024
Approved Sickle Cell Drug Fails to Beat Placebo in Trial
Approved Sickle Cell Drug Fails to Beat Placebo in Trial March 14, 2025
A female reporter holding two microphones takes notes on a pad
Opinion | ‘We See Death as a Failure’: What We Heard This Week November 10, 2024
An illustration drawn with pencil and colored digitally shows a row of hands dropping ballot envelopes into a large box in the center of the image. Inside of the ballot box is a senior male judge, who is ripping a paper in half that says, "YES."
Voters Backed Abortion Rights But State Judges Have Final Say – KFF Health News January 14, 2025
▲
The News Link | © 2025 | News